Extension of the approval period of some active substances

(1)

Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011 (2) sets out the active substances deemed to have been approved under Regulation (EC) No 1107/2009 whereas Part B of that Annex sets out the active substances approved under Regulation (EC) No 1107/2009 and Part E sets out the active substances approved under Regulation (EC) No 1107/2009 as candidates for substitution.

(2)

Commission Implementing Regulation (EU) 2021/2068 (3) extended the approval period of the active substances mecoprop-P, metiram and pyraclostrobin until 31 January 2023 and of the active substances fluazinam, flutolanil and mepiquat until 28 February 2023. Commission Implementing Regulation (EU) 2018/670 (4) extended the approval period of the active substance buprofezin until 31 January 2023. Commission Implementing Regulation (EU) 2017/1527 (5) extended the approval period of the active substance cyflufenamid until 31 March 2023.

(3)

The approval of the active substance benzovindiflupyr is set to expire on 2 March 2023 in accordance with Commission Implementing Regulation (EU) 2016/177 (6).

(4)

The approval of the active substance lambda-cyhalothrin is set to expire on 31 March 2023 in accordance with Commission Implementing Regulation (EU) 2016/146 (7).

(5)

The approval of the active substance metsulfuron-methyl is set to expire on 31 March 2023 in accordance with Commission Implementing Regulation (EU) 2016/139 (8).

(6)

The approval of the active substance phosphane is set to expire on 31 March 2023 in accordance with Commission Implementing Regulation (EU) No 1043/2012 (9).

(7)

Applications for the renewal of the approval of those active substances were submitted in accordance with Commission Implementing Regulation (EU) No 844/2012 (10).

(8)

The approvals of those active substances are likely to expire before a decision has been taken on their renewal because the decision-making procedure as regards the renewal has been delayed. Therefore, and as this delay is for reasons beyond the control of the applicants, it is necessary to extend their approval periods to enable the completion of the assessment required in order to take a decision on the applications for renewal of approval.

(9)

In particular, an extension of the approval period is required for the active substances fluazinam, flutolanil, mecoprop-P, mepiquat, metiram and pyraclostrobin to provide the time necessary to carry out an assessment relating to endocrine disrupting properties of those active substances in accordance with the procedure set out in Articles 13 and 14 of Implementing Regulation (EU) No 844/2012.

(10)

In case the Commission is to adopt a Regulation providing that the approval of an active substance referred to in the Annex to this Regulation is not renewed because the approval criteria are not satisfied, the Commission is to set the expiry date at the same date as before this Regulation or at the date of the entry into force of the Regulation providing that the approval of the active substance is not renewed, whichever date is later. As regards cases where the Commission is to adopt a Regulation providing for the renewal of the approval of an active substance referred to in the Annex to this Regulation, the Commission will endeavour to set, as appropriate under the circumstances, the earliest possible application date.

(11)

Implementing Regulation (EU) No 540/2011 should therefore be amended accordingly.

(12)

Taking into account that the current approval of buprofezin, mecoprop-P, metiram and pyraclostrobin expires on 31 January 2023, this Regulation should enter into force as soon as possible.

(13)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,